Management of synchronous lateral pelvic nodal metastasis in rectal cancer in the era of neoadjuvant chemoradiation: A systemic review

Table 2 Outcomes of total mesorectal excision only in suspicious lateral pelvic lymph node metastases

Ref.	Primary surgery	T stage	No. of patients with s-LLNM	No. of “Responders” post CRT	Recurrence	Overall survival	Disease free survival
Kim et al[10]	Sphinc-sav1 83%; sphinc-sac3 17%	All T3/4	157	98 (62%)	LR 15%; SR+LR 6%	5-yr2 85.7%; 5-yr4 74.9%	5-yr2 76.6%; 5-yr4 56.9%
Inoue et al[11]	Sphinc-sav1 63%; sphinc-sac3 37%	All T3/4	19	7 (37%)	3-yr LR 12.5%	5-yr2 84.8%; 5-yr4 72.9%	5-yr2 77.1%; 5-yr4 32.4%
Kim et al[12]	NA	All T2/3/4	212	NA	5-yr LR 36%	5-yr 70.3%5	5-yr 51.4%5
MECURY Study group[18]	NA	T1/2 18%; T3/4 82%	38	NA	NA	NA	5-yr 42%
Dharnarajan et al[13]	Sphinc-sav1 77%; sphinc-sac3 23%	T1/216%; T3/4 83%	30	NA	13%	5-yr 54%	5-yr 42%
Kim et al[14]	Either Sphinc-sav/sac	All T3/4	64	46 (72%)	19.5%2; 44.4%4	NA	NA

¹Sphincter-saving.

²Radiological responder post CRT.

³Sphincter-sacrificing.

⁴Radiological non-responder post CRT.

⁵Average value taken. s-LLNM: Suspicious lateral pelvic lymph node metastases; CRT: Chemoradiation therapy; LR: Local recurrence; SR: Systemic recurrence; NA: Not available.